-
1
المؤلفون: M. Opdam, V. van der Noort, M. Kleijn, A. Glas, I. Mandjes, S. Kleiterp, F. S. Hilbers, D. T. Kruger, A. D. Bins, P. C. de Jong, P. P. J. B. M. Schiphorst, T. van Dalen, B. Flameling, R. C. Rietbroek, A. Beeker, S. M. van den Heiligenberg, S. D. Bakker, A. N. M. Wymenga, I. M. Oving, R. M. Bijlsma, P. J. van Diest, J. B. Vermorken, H. van Tinteren, S. C. Linn
المساهمون: Oncology, CCA - Cancer Treatment and Quality of Life, Internal medicine
المصدر: Breast cancer research and treatment, 194(2), 265-278. Springer New York
Breast cancer research and treatment
Breast Cancer Research and Treatment, 194(2), 265-278. Springer New York
Opdam, M, van der Noort, V, Kleijn, M, Glas, A, Mandjes, I, Kleiterp, S, Hilbers, F S, Kruger, D T, Bins, A D, de Jong, P C, Schiphorst, P P J B M, van Dalen, T, Flameling, B, Rietbroek, R C, Beeker, A, van den Heiligenberg, S M, Bakker, S D, Wymenga, A N M, Oving, I M, Bijlsma, R M, van Diest, P J, Vermorken, J B, van Tinteren, H & Linn, S C 2022, ' Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature ', Breast Cancer Research and Treatment, vol. 194, no. 2, pp. 265-278 . https://doi.org/10.1007/s10549-022-06618-zمصطلحات موضوعية: Cancer Research, Antineoplastic Agents, Hormonal, Overtreatment, Endocrine treatment, MammaPrint 70-gene signature, Early breast cancer, Breast Neoplasms, Prognosis, Postmenopause, Tamoxifen, Oncology, Chemotherapy, Adjuvant, Humans, Postmenopausal, Female, Human medicine